NASDAQ · OVID
Healthcare · Biotechnology
$2.16
Up+$0.07 (+3.25%)
Updated Oct 27, 2026, 5:46 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OVID
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
OVID closed at $2.16 after 21 trading sessions, down 12.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.19 | $2.22 | $2.1213 | $2.155 | 844.07K |
| Oct 23, 2026 | $2.31 | $2.32 | $2.12 | $2.16 | 2.02M |
| Oct 22, 2026 | $2.45 | $2.50 | $2.34 | $2.37 | 1.18M |
| Oct 21, 2026 | $2.37 | $2.65 | $2.345 | $2.47 | 5.01M |
| Oct 20, 2026 | $2.19 | $2.46 | $2.175 | $2.36 | 3.67M |
| Oct 19, 2026 | $2.18 | $2.225 | $2.14 | $2.17 | 1.64M |
| Oct 16, 2026 | $2.26 | $2.30 | $2.11 | $2.15 | 1.33M |
| Oct 15, 2026 | $2.21 | $2.31 | $2.19 | $2.26 | 1.33M |
| Oct 14, 2026 | $2.18 | $2.255 | $2.09 | $2.19 | 1.64M |
| Oct 13, 2026 | $2.41 | $2.415 | $2.18 | $2.19 | 1.64M |
| Oct 12, 2026 | $2.45 | $2.4933 | $2.394 | $2.41 | 876.04K |
| Oct 9, 2026 | $2.37 | $2.475 | $2.33 | $2.46 | 1.41M |
| Oct 8, 2026 | $2.32 | $2.36 | $2.29 | $2.34 | 1.65M |
| Oct 7, 2026 | $2.36 | $2.46 | $2.34 | $2.36 | 1M |
| Oct 6, 2026 | $2.42 | $2.44 | $2.27 | $2.37 | 1.74M |
| Oct 5, 2026 | $2.38 | $2.47 | $2.29 | $2.34 | 1.2M |
| Oct 2, 2026 | $2.47 | $2.48 | $2.33 | $2.38 | 2.17M |
| Oct 1, 2026 | $2.49 | $2.53 | $2.42 | $2.43 | 1.35M |
| Sep 30, 2026 | $2.54 | $2.605 | $2.48 | $2.49 | 1.44M |
| Sep 29, 2026 | $2.47 | $2.54 | $2.42 | $2.54 | 1.16M |
| Sep 28, 2026 | $2.40 | $2.49 | $2.35 | $2.46 | 1.19M |
The latest Smart Investors Daily articles mentioning OVID.
Company
Market Activity
Research & News
OVID research
Company profile and research snapshot.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Wolfe Research | Outperform | — |
| Oct 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 6, 2026 | Guggenheim | Buy | — |
| Oct 5, 2026 | Guggenheim | Buy | — |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 15, 2026
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
Benzinga · Oct 9, 2026
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
Yahoo · Oct 8, 2026
The latest fair value estimate for Ovid Therapeutics has shifted from US$5.47 to US$6.02 per share, keeping it within the current analyst price target range of US$5 to US$8. Research firms are linking this move to fresh discussion around OV329. More constructive views point to its clinical profile and the broader epilepsy pipeline, while cautious voices highlight execution risk and long timelines into 2026. As you read on, you will see how these moving parts shape the evolving analyst...
Benzinga · Oct 6, 2026
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OVID.
